SLCO1B1在肝细胞癌中的表达及其对患者预后的影响

Expression of SLCO1B1 in Hepatocellular Carcinoma and its Effect on Prognosis

目的 研究SLCO1B1在肝细胞癌组织中的表达变化及其与免疫细胞浸润程度的关系,分析其对肝癌患者预后的影响。方法 通过TIMER2.0数据库分析SLCO1B1在肝细胞癌及癌旁组织中的表达差异,利用TIMER数据库分析肝细胞癌中SLCO1B1的表达与免疫细胞浸润的关系,并评估肿瘤浸润性免疫细胞对肝细胞癌预后的预测价值;利用Kaplan-Meier plotter数据库进行肝细胞癌生存曲线分析,分析在不同的临床病理条件下SLCO1B1的表达水平与肝细胞癌患者临床预后的相关性;使用TISIDB数据库检测肝细胞癌中SLCO1B1基因表达与28种淋巴细胞浸润的相关性;通过GEPIA数据库分析SLCO1B1和免疫细胞标记基因的相关性。结果 SLCO1B1在肝细胞癌的表达水平低于癌旁组织(P<0.05);SLCO1B1高表达患者的总生存期(OS)、无复发生存期(RFS)、无进展生存期(PFS)、疾病特异性生存期(DSS)均高于低表达患者(P<0.05),且SLCO1B1的表达在肝细胞癌患者的某些临床特征(如男性、亚洲人、饮酒、未感染肝炎病毒等)中具有预后意义;SLCO1B1表达水平与B细胞、CD8^(+)T细胞、CD4^(+)T细胞、巨噬细胞、中性粒细胞、树突状细胞等免疫细胞在肝细胞癌组织中的浸润水平呈负相关(P<0.05)。结论 肝细胞癌组织中的SLCO1B1表达降低,其是一种与免疫浸润相关的肝细胞癌预后生物标志物,并可能作为肝癌新的治疗靶点。

Objective To study the expression of SLCO1B1 in hepatocellular carcinoma and its relationship with the degree of immune cell infiltration, and to analyze its effect on the prognosis of patients with hepatocellular carcinoma. Methods The gene SLCO1B1 with distinct expression differences in hepatocellular carcinoma and adjacent tissues was screened out by TIMER2.0 database. The relationship between the expression of SLCO1B1 in hepatocellular carcinoma and the infiltration of immune cells was analyzed by TIMER database, and the predictive value of tumor-infiltrating immune cells for the prognosis of hepatocellular carcinoma was evaluated. Kaplan-Meier plotter database was used to analyze the survival curve of hepatocellular carcinoma, and the correlation between the expression level of SLCO1B1 and the clinical prognosis of patients with hepatocellular carcinoma was obtained under different clinicopathological conditions. The correlation between SLCO1B1 gene expression and28 kinds of lymphocyte infiltration was detected by TISIDB database. Finally, the correlation between SLCO1B1 and immune cell marker genes was analyzed by GEPIA database.Results The expression level of SLCO1B1 in hepatocellular carcinoma was lower than that in adjacent tissues( P <0.05). The overall survival(OS), recurrence-free survival(RFS), progression-free survival(PFS) and disease-specific survival(DSS) of patients with high expression of SLCO1B1 were higher than those of patients with low expression( P<0.05), and the expression of SLCO1B1 had prognostic significance in some clinical features of patients with hepatocellular carcinoma(such as male, Asian, drinking, uninfected hepatitis virus, etc.);the expression level of SLCO1B1 was negatively correlated with the infiltration levels of B cells, CD8^(+)T cells, CD4^(+)T cells, macrophages, neutrophils,dendritic cells and other immune cells in hepatocellular carcinoma tissues( P <0.05).Conclusion SLCO1B1 is down-regulated in hepatocellular carcinoma tissues, which is a prognostic biomarker of hepatocellular carcinoma associated with immune infiltration and may serve as a new therapeutic target for hepatocellular carcinoma.